Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,484.80
(
-0.99%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
105.10
(
0.00%
)
Bitcoin
68,545.64
(
-0.50%
)
News Focus
News Focus
Post# of 257269
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

ThomasS

Send PM Follow Ignore
Followers 12
Posts 2277
Boards Moderated 0
Alias Born 05/05/2005

ThomasS

Re: DewDiligence post# 71010

Wednesday, 01/07/2009 7:47:36 AM

Wednesday, January 07, 2009 7:47:36 AM

Post# of 257269
BioMarin-BMRN licensing deal with La Jolla makes sense, says Citigroup
Citigroup believes BioMarin's in-licensing of Riquent from La Jolla Pharmaceutical (LJPC) makes sense as the company put only $52.5M at risk for the option of participation of in a Phase III program for a sizable indication with high unmet medical need. Citigroup maintains a Buy rating on BMRN shares.

"One word sums up probably the responsibility of any vice
president, and that one word is 'to be prepared.'" - Dan
Quayle

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today